No Data
No Data
China Resources Double-Crane Pharmaceutical (600062.SH): Some products have obtained supplementary drug application approval letters and chemical raw materials market application approval letters.
China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 9th that it has received the Drug Supplement Approval Notice for Aminophylline Injection from the National Medical Products Administration. Its wholly-owned subsidiary, Shuanghe Pharmaceutical (Shangqiu) Co., Ltd., received the Approval Notice for Active Pharmaceutical Ingredient Market Authorization Application from the NMPA.
Investors Aren't Buying China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 29x, you may consider China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) as a highly attracti
Double-Crane Pharmaceutical Unit Gets China Nod for Influenza Drug
China's medical products administrator granted China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Jingxi Shuanghe Pharmaceutical a drug registration certificate for its peramivir inje
China Resources Double-Crane Pharmaceutical (600062.SH): The pharmaceutical registration certificate for the injection of Parmiwe has been obtained.
China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 2nd that its wholly-owned subsidiary, Xi'an Jingxi Shuanghe Pharmaceuticals Co., Ltd., received the Drug Registration Certificate for parameve injection issued by the National Drug Administration. Parameve Injection is used to treat influenza A or B.
CR Double-Crane Pharmaceutical Registers Antibiotic, Ulcer Medications in China
China Resources Double-Crane Pharmaceutical (SHA:600062) secured drug registrations for its antibiotic and ulcer medications in China. Levofloxacin tablets are mainly used to treat or prevent infectio
China Resources Double-Crane Pharmaceutical (600062.SH): Some of its subsidiary's products have obtained pharmaceutical registration certificates.
On June 27, Gelunhui announced that its wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical's Limin Pharmaceutical (Jinan) Co., Ltd., received a Drug Registration Certificate for Levofloxacin tablets from the National Medical Products Administration. Its another wholly-owned subsidiary, Double-Crane Pharmaceutical (Hainan) Co., Ltd., received a Drug Registration Certificate for Injection Roxatidine Acetate Hydrochloride from the National Medical Products Administration. Levofloxacin is a quinolone antibiotic used mainly to treat or prevent infections proven or highly suspected to be caused by sensitive bacteria. Roxatidine Acetate Hydrochloride for Injection is a histamine H2 receptor antagonist used for the treatment of upper.
No Data